MedicaidPrior AuthMedium impact
MAB June 7, 2017
Pennsylvania Medicaid (DHS)·PA · Allergy & Immunology, Pulmonology, Pharmacy·Provider Bulletin
Effective date
Jun 6, 2017
We identified it
Jun 20, 2026
Summary
Pennsylvania Medical Assistance (Medicaid) now requires prior authorization for all Cinqair (reslizumab) prescriptions used to treat severe eosinophilic asthma. The drug must be prescribed by specialists and meet strict clinical criteria including blood eosinophil count ≥400/microL and failure of standard asthma treatments.
Action Required
Immediately: Pharmacies and prescribers in Pennsylvania must obtain prior authorization before dispensing or prescribing Cinqair (reslizumab) for Medical Assistance patients. Prescribers must document severe asthma diagnosis with spirometry results, blood eosinophil count ≥400/microL, failure of standard treatments, and specialist consultation. Use PROMISe system to submit prior authorization requests following Section I procedures. Initial approvals valid for 6 months, renewals for 12 months.